China’s First Insulin Tender Hits Multinationals Hard
Executive Summary
An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.
You may also be interested in...
Multinationals Return To Growth In China In First Half
AZ and Novo Nordisk reported sales growth from innovative new drugs in China, despite the lingering impact of the country's volume-based procurement scheme. Meanwhile, Novartis, Sanofi and Roche saw gains for new antibody and cancer drugs, along with solid vaccine sales.
Pharma Execs: China Slowly Returning To Growth But Uncertainty Remains
Just how dynamic is the China market for multinationals? AstraZeneca is seeing growth returning while Pfizer is finding it challenging to estimate Paxlovid demand, Sanofi is encouraged by volume gains and GSK is predicting a "sizeable" rebound. Top executives from Novartis and Roche also shed light on other challenges facing global pharma firms in the world's second-largest pharma market as they reported annual results.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.